© Reuters.
On Friday, Madrigal Pharmaceuticals (NASDAQ:) saw its price target increased to $390 from $349, retaining an Outperform rating by TD Cowen. The adjustment follows the FDA’s approval of Madrigal’s THR-β agonist Rezdiffra (resmetirom) for the treatment of NASH with moderate to advanced fibrosis, identified as F2/F3 stages, notably without the need for a biopsy in the indication language.
The analyst from TD Cowen highlighted the “very clean” label of Rezdiffra, which lacks market-limiting warnings, monitoring requirements, or contraindications. This approval is significant for Madrigal Pharmaceuticals as it sets the stage for the commercial distribution of the drug.
Alongside the FDA approval, Madrigal announced a wholesale acquisition cost (WAC) of $47,400 for Rezdiffra, with plans for specialty distribution channels. The company’s financial outlook, as projected by the analyst, includes forecasted sales of $97 million in the fiscal year 2024 and an anticipation of peak sales reaching $4.9 billion by the year 2031.
Madrigal Pharmaceuticals’ stock may see investor attention following this positive regulatory development and the subsequent financial projections. The new price target by TD Cowen reflects a vote of confidence in the potential market performance of Rezdiffra and Madrigal’s strategic positioning in the pharmaceutical industry.
InvestingPro Insights
Following the recent FDA approval of Rezdiffra, Madrigal Pharmaceuticals (NASDAQ:MDGL) has garnered significant attention. The market’s reaction to this event can be further understood by examining key financial metrics and expert analysis provided by InvestingPro.
As of the latest update, Madrigal Pharmaceuticals holds a market capitalization of approximately $4.85 billion. Despite a challenging financial outlook with a negative Price/Earnings (P/E) ratio of -12.33 and an adjusted P/E ratio for the last twelve months as of Q4 2023 at -12.97, the company’s stock price has experienced a substantial 38.48% increase over the past six months. This rally could be indicative of investor optimism surrounding the commercial potential of Rezdiffra.
InvestingPro Tips suggest caution, noting that analysts have recently revised earnings downwards for the upcoming period and do not anticipate the company to be profitable this year. Additionally, Madrigal’s gross profit margins are considered weak, and the stock price often moves in opposition to the market, which may add a layer of unpredictability to its performance.
For investors seeking a deeper dive into Madrigal Pharmaceuticals’ financials and future prospects, there are 11 additional InvestingPro Tips available, which can be accessed by visiting InvestingPro. To enrich your investment analysis, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.